HRAS as a potential therapeutic target of salirasib RAS inhibitor in bladder cancer.

Abstract excerpt

The active form of the small GTPase RAS binds to downstream effectors to promote cell growth and proliferation. RAS signal enhancement contributes to tumorigenesis, invasion, and metastasis in various different cancers. HRAS proto-oncogene GTPase (HRAS), one of the RAS isoforms, was the first human oncogene for which mutations were reported in T24 bladder cancer (BC) cells in 1982, and HRAS mutation or...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Gene Knockdown Techniques
• Share to Glycolysis